[extra Quality] | Nagrath Lab

The clinical trial began six months later. Three hundred patients. Early detection rates for ovarian, pancreatic, and lung cancers—all above ninety-five percent. The paper in Nature Biomedical Engineering would call it “a paradigm shift in liquid biopsy.” The press would call it “a breathalyzer for cancer.”

She draped a blanket over his shoulders and whispered to the empty lab: “Whisper in a hurricane.” nagrath lab

“Day 407,” he murmured into a recorder. “The plasmonic substrate has isolated exosomal signatures from a stage-0 pancreatic lesion. Sensitivity: 99.8 percent. Specificity: unchanged.” The clinical trial began six months later